close
6 Pages
6Pages write-ups are some of the most comprehensive and insightful I’ve come across – they lay out a path to the future that businesses need to pay attention to.
— Head of Deloitte Pixel
At 500 Startups, we’ve found 6Pages briefs to be super helpful in staying smart on a wide range of key issues and shaping discussions with founders and partners.
— Thomas Jeng, Director of Innovation & Partnerships, 500 Startups
6Pages is a fantastic source for quickly gaining a deep understanding of a topic. I use their briefs for driving conversations with industry players.
— Associate Investment Director, Cambridge Associates
In-Kind Partners
TED
500 Startups
Used at top MBA programs including
Stanford Graduate School of Business
University of Chicago Booth School of Business
Wharton School of the University of Pennsylvania
Kellogg School of Management at Northwestern University
Summary
  • With the coming conclusion of the MAPP1/MAPP2 Phase 3 clinical trials, MDMA could become widely available as part of an FDA-approved, therapist-supervised prescription treatment for PTSD (post-traumatic stress disorder) as soon as 2023.
  • Psychedelic drugs are demonstrating therapeutic potential for treating an array of mental conditions such as PTSD, treatment-resistant depression, addiction (e.g. opioids, heroin, cocaine, smoking, alcohol), anorexia, and anxiety.
  • Society and policymakers are signaling a greater willingness to decriminalize psychedelics for medical uses. Regulators, in turn, are indicating greater openness to therapies that represent a step-up in efficacy over available alternatives.
  • Some are already concerned that psychedelics are becoming the next “cannabis bubble.” While psychedelics are showing promise, most of the industry players are still at a relatively early stage – suggesting they may be overvalued in this frothy market.
  • The stage is set for a new, innovative class of prescription treatments that can address persistent mental conditions. The winners among the psychedelic pharma companies will have a foothold in an emerging $100B market.
Become a Member to read the full brief
Get unlimited access to full-length 6Pages Briefs, 3 Shifts Editions, and the searchable repository.
Become a Member
Become a Member
Already a Member?
All Briefs
See more briefs

Get unlimited access to all our briefs.
Make better and faster decisions with context on far-reaching shifts.
Become a Member
Become a Member
Get unlimited access to all our briefs.
Make better and faster decisions with context on what’s changing now.
Become a Member
Become a Member